EUCTR2005-003610-15-SE进行中（未招募）不适用
An International, randomised, open trial comapring a rituximab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of 'generalised' ANCA associated vasculitis. - RITUXVAS
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(all four must be present)
- •1.A new diagnosis of WG, MP or renal-limited vasculitis (RLV)(appendix 1)
- •2.Renal involvement attributable to active WG, MP or RLV with at least one of the following:
- •a)biopsy demonstrating necrotizing glomerulonephritis.
- •b)red cell casts on urine microscopy or = ++ haematuria
- •3.ANCA positivity ANCA positivity requires either (a) or (b)
- •(a) PR3-ANCA or a typical cANCA pattern by indirect immunofluorescence (IIF), preferably confirmed by anti-PR3 ELISA.
- •(b) MPO-ANCA determined by ELISA requires demonstration of pANCA, and pANCA by IIF requires confirmation by anti-MPO ELISA .
- •4. Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Previous cyclophosphamide, greater than 2 weeks of oral or one IV pulse = 15mg/kg cyclophosphamide
- •2.Co-existence of another multisystem autoimmune disease, e.g. SLE, Churg Strauss Syndrome, Henoch Schonlein Purpura, rheumatoid vasculitis, essential mixed cryoglobulinaemia, anti-glomerular basement membrane antibody positivity
- •3.Hepatitis B e antigen positive or Hepatitis C antibody positive.
- •4.Known HIV positive (HIV testing will not be a requirement for this trial).
- •5.Previous malignancy (usually exclude unless agreed with trial co-ordinator).
- •6.Pregnancy, breast feeding or inadequate contraception if female.
- •7Allergy to a study medication
- •8Live Vaccine within last 4 weeks
研究者
相似试验
进行中（未招募）
1 期
An international, randomised, open trial comparing a rituximab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of 'generalised' ANCA associated vasculitis. - RITUXVASAnti neutophil cytoplasmic antibody (ANCA) associated vasculitisEUCTR2005-003610-15-GBCambridge University Hospitals NHS Foundation Trust
已完成
不适用
An international study designed to answer reliably whether, for women who have hormone sensitive early breast cancer (the most common type of breast cancer), 10 years of adjuvant tamoxifen (a hormone treatment) confers more benefit than just 5 years in terms of reducing the risk of relapse and improving overall, long-term survival: Adjuvant Tamoxifen - Longer Against Shorter (ATLAS)Operable, oestrogen receptor positive breast cancer already trated with ~5 years of adjuvant tamoxifenMalignant neoplasm of breastCancerISRCTN19652633niversity of Oxford (UK)15,262
进行中（未招募）
1 期
An international, randomised, open label trial comparing a rituximab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of active, ‘generalised’ ANCA associated vasculitis. - RITUXVASThe ANCA associated vasculitides (AASV), namely Wegener’s granulomatosis, microscopic polyangiitis, and renal limited vasculitis.EUCTR2005-003610-15-CZAddenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
已完成
2 期
An international, randomised, open label trial comparing a rituxmab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of active, 'generalised' ANCA associated vasculitisWegener granulomatosis1000381610038430NL-OMON29858Academisch Medisch Centrum2
已完成
不适用
An international, randomised, open label trial comparing a rituximab-based regimen with a standard cyclophosphamide/azathioprine based regimen in the treatment of active, generalised anti-neutrophilic cytoplasmic antibodies associated vasculitisANCA associated vasculitisISRCTN28528813Cambridge University Hospitals NHS Foundation Trust (UK)40